ARVN
ARVN
NASDAQ · Pharmaceuticals

Arvinas Inc

$10.64
+0.35 (+3.40%)
As of Mar 25, 2:16 PM ET ·
Financial Highlights (FY 2026)
Revenue
239.91M
Net Income
-73,815,119
Gross Margin
Profit Margin
-30.8%
Rev Growth
+26.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 45.0% 45.0%
Operating Margin -45.1% -40.6% 18.2% 21.8%
Profit Margin -30.8% -29.2% 16.7% 16.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 239.91M 190.46M 233.97M 279.36M
Gross Profit 105.26M 125.68M
Operating Income -108,269,404 -77,359,847 42.69M 60.95M
Net Income -73,815,119 -52,741,828 39.13M 45.19M
Gross Margin 45.0% 45.0%
Operating Margin -45.1% -40.6% 18.2% 21.8%
Profit Margin -30.8% -29.2% 16.7% 16.2%
Rev Growth +26.0% +26.0% +1.6% -9.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 321.2K 321.2K 97.71M 100.55M
Total Equity 356.90M 356.90M 421.09M 435.13M
D/E Ratio 0.00 0.00 0.23 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -105,884,148 -79,858,638 67.61M 80.57M
Free Cash Flow 28.90M 31.70M